Aethlon Medical (NASDAQ:AEMD) Now Covered by StockNews.com

StockNews.com started coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a report released on Thursday. The brokerage issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Aethlon Medical in a research report on Monday, March 10th.

Aethlon Medical Price Performance

Shares of AEMD stock opened at $0.43 on Thursday. The company’s fifty day simple moving average is $0.58 and its 200-day simple moving average is $0.50. The firm has a market cap of $6.22 million, a PE ratio of -0.27 and a beta of 1.80. Aethlon Medical has a 12 month low of $0.24 and a 12 month high of $1.85.

Aethlon Medical (NASDAQ:AEMD) last announced its quarterly earnings data on Wednesday, February 12th. The medical equipment provider reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.09. On average, equities analysts predict that Aethlon Medical will post -0.73 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aethlon Medical

Institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC acquired a new position in Aethlon Medical during the fourth quarter worth $25,000. Allegiance Financial Group Advisory Services LLC acquired a new position in Aethlon Medical during the fourth quarter worth $26,000. Sassicaia Capital Advisers LLC acquired a new position in Aethlon Medical during the fourth quarter worth $31,000. Virtu Financial LLC acquired a new position in Aethlon Medical during the fourth quarter worth $81,000. Finally, Boothbay Fund Management LLC acquired a new position in Aethlon Medical during the fourth quarter worth $186,000. 1.99% of the stock is currently owned by institutional investors and hedge funds.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.